[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
Indian drug firm Wockhardt announced in early December that its Chikalthana plant at Aurangabad in Maharashtra received a GMP certificate from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) after an inspection of the plant, the Economic Times of India is reporting. In January, MHRA expanded its import ban on products coming from Wockhardt’s Chikalthana plant that began in 2013 (IPQ January 20, 2015). The plant received a warning letter from FDA in July 2013 (IPQ April 28 2014).
[/membership]
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
